CCR9 and inflammatory bowel disease: Despite this study and our previous work [23] which bring together in vivo, in vitro, and in silico evidence of the relevance of the CCR9:DRD5 heteromer in T-cells recruitment into the colon upon inflammatory conditions, the therapeutic potential should be tested in vivo using preclinical models of IBD in the future.